Clinical Applications Of Noncoding Rnas In Cancer

Clinical Applications of Noncoding RNAs in Cancer summarizes the existing strategies, advances, and future opportunities on the role of noncoding RNAs in cancer patients. Established clinicians and researchers from all around the world share their views and expertise and provide readers with invaluable knowledge on the subject. This book provides a comprehensive collection of information on the utility of noncoding RNAs in the diagnosis, prognosis, and therapy of cancer. It also discusses the evolutionary significance of noncoding RNAs and how the molecular tools such as RNA-seq, RNA-FISH, ic-SHAPE, and quantitative real-time PCR help in the detection and elucidation of the functions of noncoding RNAs. Additionally, the challenges associated with noncoding RNA approaches and future developments are discussed. It is a valuable resource for cancer researchers, oncologists, clinicians, and other biomedical field members who want to learn more about noninvasive ways to diagnose and efficiently treat diverse cancer types. Presents a beginning chapter summary to help readers understand the content thoroughly Encompasses detailed description of information from clinical studies on noncoding RNAs in cancer therapy Discusses one cancer type per chapter making the content easy to reference

"Non-coding RNA Transcripts in Cancer Therapy: Pre-clinical and Clinical Implications" provides a new insight towards role of non-coding RNAs molecules including microRNAs, long non-coding RNAs and circular RNAs in cancer. The reason of focusing on cancer is that this malignant disease is responsible for high death around the world and after cardiovascular diseases, it is a leading cause of death. In the current book, the basic information and knowledge about ncRNAs, their biogenesis and their biological functions are covered. It is shown that ncRNAs can regulate expression level of genes at transcriptional and post-transcriptional levels and therefore, ncRNAs are master and key players in molecular pathways. Then, the impact of regulation of molecular pathways by ncRNAs on important molecular mechanisms such as proliferation, metastasis, epithelial-to-mesenchymal transition, apoptosis and autophagy are described. All of these aspects are integrated in cancer and for treatment of this disease. In case of miRNAs, their biogenesis and biological functions in physiological conditions are described. Then, impact of miRNAs on proliferation, metastasis, therapy response (drug resistance and radio-resistance) is described. For lncRNAs and circRNAs, a same way is followed and their biogenesis and functional roles in cells are discussed. At the next step, function of lncRNAs and circRNAs in regulating proliferation, metastasis and therapy response (chemoresistance and radio-resistance) is introduced. These subjects are discussed based on pre-clinical studies and in order to make the book more comprehensive and broaden its scope, the function of exosomal ncRNAs in diagnosis and prognosis of cancer patients is described.

Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic. Highlights the potential of epigenetic alterations in cancer for drug development Covers the tools and methods for epigenetic drug discovery, preclinical and clinical testing, and clinical implications of epigenetic therapy Provides important information regarding putative epigenetic targets, epigenetic technologies, networks and consortia for epigenetic drug discovery and routes for translation

Noncoding RNAs (ncRNAs) are an attractive research field in the RNA world. ncRNAs play important roles in regulating gene expression in animals, plants, and various human diseases. It is clear that current and further research on ncRNAs will change our knowledge of the nature of genome composition by editing previous dogmas. This book provides an overview of current knowledge on ncRNA research by dealing with miRNA and ncRNA-related human diseases, plant miRNA markers, and the roles of lncRNAs in cancer and epigenetics.

The discovery of microRNAs and its role as gene expression regulators in human carcinogenesis represents one of the most important scientific achievements of the last decade. More recently, other non-coding RNAs have been discovered and its implications in cancer are emerging as well, suggesting a broader than anticipated involvement of the non-coding genome in cancer. Moreover, completely new and unexpected functions for microRNAs are being revealed, leading to the identification of new anticancer molecular targets. This book represents a comprehensive guide on non-coding RNAs and cancer, spanning from its role as cancer biomarkers, to providing the most useful bioinformatic tools, to presenting some of the most relevant discoveries, which indicates how these fascinating molecules act as fine orchestrators of cancer biology.

Cancer and Noncoding RNAs offers an in-depth exploration of noncoding RNAs and their role in epigenetic regulation of complex human disease, most notably cancer. In addition to examining microRNAs, this volume provides a unique evaluation of more recently profiled noncoding RNAs now implicated in carcinogenesis, including lncRNAs, piRNAs, circRNAs, and tRNAs, identifying differences in function between these noncoding RNAs and how they interact with the rest of the epigenome. A broad range of chapters from experts in the field detail epigenetic regulation of various cancer types, along with recent next generation sequencing technologies, genome-wide association studies (GWAS) and bioinformatics approaches. This book will help researchers in genomic medicine and cancer biology better understand the role of noncoding RNAs in epigenetics, aiding in the development of useful biomarkers for diagnosis, prognosis and new RNA-based disease therapies. Provides a comprehensive analysis of noncoding RNAs implicated in epigenetic regulation of gene expression and chromatin dynamics Educates researchers and graduate students by highlighting, in addition to miRNAs, a range of noncoding RNAs newly associated with carcinogenesis Applies current knowledge of noncoding RNAs and epigenomics towards developing cancer and RNA-based disease therapies Features contributions by leading experts in the field

This contributed volume offers a comprehensive and detailed overview of the various aspects of long non-coding RNAs and discusses their emerging significance. Written by leading experts in the field, it motivates young researchers around the globe, and offers graduate and postgraduate students fascinating insights into genes and their regulation in eukaryotes and higher organisms.

This book reviews the current applications and future prospects of nanomaterials in cancer diagnostics and therapy. Nanomaterials have recently emerged as a remarkable and promising tool for cancer therapy and diagnosis, due to their broad range of intrinsic molecular properties. To overcome the current limitations of nanoparticles in drug delivery systems, attempts have been made to synthesize nanoparticles from biological materials for targeted cancer therapy. This book provides concise evaluations of various potential bio-inspired platforms that mimic natural components of the body and offer effective and versatile drug delivery systems for cancer therapy. It also assesses the potential of nanoparticles to enhance the outcomes of cancer immunotherapy via immune cell activation and tumor microenvironment modulation. The book also summarizes in the applications of nanomaterials for the detection, prevention, and treatment of solid tumors and in the treatment of leukemia and lymphomas. In closing, it discusses ethical issues in nanomedicine, including risk assessment, risk management, and risk communication during clinical trials. The book offers offers a valuable source of information for students, academics, researchers, scientists, clinicians, and healthcare professionals working in nanotechnology and cancer research.